Metabolomics-Based Methods for Disease Diagnostics

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Laboratory Medicine".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 2193

Special Issue Editor


E-Mail Website
Guest Editor
Centre of Biomedical Research, SGPGIMS Campus, Lucknow, India
Interests: determination of prognostic biomarkers for coronary artery disease using metabolomics approach; proteo-metabolomic study of prostate cancer and renal cell carcinoma

Special Issue Information

Dear Colleagues, 

Metabolic changes occur before morphological changes, and metabolomics—a novel, evolving branch of metabolic measures—involves the simultaneous identification and quantification of many small metabolites using body fluids and tissues in a single experiment; thus, it has great potential for early disease diagnosis, treatment monitoring, and real-time observation of the mechanisms of pathogenesis in underlying diseases. This gives metabolomics an advantage over classical and conventional methods of detecting underlying diseases. Metabolomics encompasses two main methods: nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). Data analysis via these high-throughput methods, whereby innovative chemometric tactics are applied, provides a unique stage for pre-clinical, clinical, and translational research and its diagnostic uses. For this Special Issue of Diagnostics, titled "Metabolomics-Based Methods for Disease Diagnostics", we welcome contributions on topics ranging from pre-clinical models to clinical metabolomics-based methods, with the aim of advancing their clinical application. We invite authors to contribute novel research and review articles presenting state-of-the-art modalities and methodologies to identify, foresee, and analytically test for signature metabolites of underlying diseases.

Dr. Ashish Gupta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolomics
  • metabonomics
  • mass spectrometry and NMR spectroscopy
  • disease diagnostics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 2940 KiB  
Article
Modulation of Neurotransmitter Pathways and Associated Metabolites by Systemic Silencing of Gut Genes in C. elegans
by Shikha Shukla, Ankit Saxena, Sanjeev K. Shukla and Aamir Nazir
Diagnostics 2023, 13(14), 2322; https://doi.org/10.3390/diagnostics13142322 - 10 Jul 2023
Cited by 2 | Viewed by 1876
Abstract
The gut is now recognized as the “second brain” of the human body due to its integral role in neuronal health and functioning. Although we know that the gut communicates with the brain via immunological factors, microbial metabolites, and neurotransmitters, the interplay of [...] Read more.
The gut is now recognized as the “second brain” of the human body due to its integral role in neuronal health and functioning. Although we know that the gut communicates with the brain via immunological factors, microbial metabolites, and neurotransmitters, the interplay of these systems remains poorly understood. To investigate this interplay, we silenced 48 genes that are exclusively or primarily expressed in the C. elegans intestine. We studied the associated effects on various aspects of neurodegeneration, including proteotoxicity induced by α-Syn expression. We also assayed behaviours, such as mobility and cognition, that are governed by various neurotransmitters. We identified nine gut genes that significantly modulated these events. We further performed HR-MAS NMR-based metabolomics to recognize the metabolic variability induced by the respective RNAi conditions of R07E3.1, C14A6.1, K09D9.2, ZK593.2, F41H10.8, M02D8.4, M88.1, C03G6.15 and T01D3.6. We found that key metabolites such as phenylalanine, tyrosine, inosine, and glutamine showed significant variation among the groups. Gut genes that demonstrated neuroprotective effects (R07E3.1, C14A6.1, K09D9.2, and ZK593.2) showed elevated levels of inosine, phenylalanine, and tyrosine; whereas, genes that aggravated neurotransmitter levels demonstrated decreased levels of the same metabolites. Our results shed light on the intricate roles of gut genes in the context of neurodegeneration and suggest a new perspective on the reciprocal interrelation of gut genes, neurotransmitters, and associated metabolites. Further studies are needed to decipher the intricate roles of these genes in context of neurodegeneration in greater detail. Full article
(This article belongs to the Special Issue Metabolomics-Based Methods for Disease Diagnostics)
Show Figures

Figure 1

Back to TopTop